Clinical trials: Pharmacokinetics of Repaglinide
Healthy
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
The main objective of this trial is to investigate the effect of multiple oral doses of BI 1569912 on the pharmacokinetics of a single oral dose of repaglinide, midazolam and bupropion (i.e.
- Trial name
- NCT06367153
- Testing
- BI 1569912, Repaglinide, Midazolam
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
The main objective of this trial is to assess the effect of multiple oral doses of zongertinib on the pharmacokinetics of midazolam, omeprazole and repaglinide.
- Trial name
- NCT06494761
- Testing
- zongertinib, midazolam, omeprazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate…
- Trial name
- NCT06092931
- Testing
- DC-806, Midazolam, Repaglinide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Healthy
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much…
- Trial name
- NCT06165146
- Testing
- Repaglinide, Pirtobrutinib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Parkinson Disease
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.
- Trial name
- NCT01536366
- Testing
- BIA 9-1067, Repaglinide
- Where
- Portugal
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants.
- Trial name
- NCT05469113
- Testing
- Repaglinide, Selpercatinib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company